Screener
Candel Therapeutics, Inc. CADL Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -81.8%— | -51.2%+47.0pp | -64.6%+75.0pp | —— | —— | |
| Liquidity | ||||||
| Current ratio | 16.1×+9.1× | 28×+23.4× | 13.5×+10.7× | 8.2×+7.1× | 7×+5.4× | |
| Leverage | ||||||
| Debt-to-equity | 0×-0.1× | 0×-0.1× | 0.1×-0.1× | 0.1×— | 0.1×— | |
| Per Share | ||||||
| Book value per share | $1.70-2.9% | $2.21+62.3% | $0.98-53.2% | $1.46+406% | $1.75+625% | |
| Valuation | ||||||
| Market capitalization | $777.43M+162% | $358.91M+34.5% | $310.18M-19.7% | $279.97M+35.2% | $243M+34.2% | |
| Price / book | 6.2×+2.5× | 2.6×-1.0× | 6×+0.2× | 3.5×— | 2.7×— |
FAQ
- Where do Candel Therapeutics, Inc.'s ratios come from?
- Every ratio is computed from Candel Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.